2008 related articles for article (PubMed ID: 28482261)
21. Minimizing the Risk of Bleeding with NOACs in the Elderly.
Kundu A; Sardar P; Chatterjee S; Aronow WS; Owan T; Ryan JJ
Drugs Aging; 2016 Jul; 33(7):491-500. PubMed ID: 27174293
[TBL] [Abstract][Full Text] [Related]
22. Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Türk UÖ; Acar RD; Akgün T; Emren V; Kanat S; Karacağlar E; Kepez A; Kul Ş; Özel E; Şimşek E; Yakar Tülüce S; Tülüce K; Camm AJ
Turk Kardiyol Dern Ars; 2020 Apr; 48(3):289-303. PubMed ID: 32281950
[TBL] [Abstract][Full Text] [Related]
23. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
24. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
26. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
[TBL] [Abstract][Full Text] [Related]
27. The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Lip GYH
Int J Clin Pract; 2019 Feb; 73(2):e13285. PubMed ID: 30334313
[TBL] [Abstract][Full Text] [Related]
28. Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Patti G; Haas S
J Cardiovasc Pharmacol; 2020 Oct; 77(1):11-21. PubMed ID: 33060545
[TBL] [Abstract][Full Text] [Related]
29. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
31. [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Mohebbi N
Praxis (Bern 1994); 2018 Jun; 107(13):683-687. PubMed ID: 29921184
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulation in Patients with Chronic Kidney Disease.
Elenjickal EJ; Travlos CK; Marques P; Mavrakanas TA
Am J Nephrol; 2024; 55(2):146-164. PubMed ID: 38035566
[TBL] [Abstract][Full Text] [Related]
33. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
34. [New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].
Riva L; Di Pasquale G
G Ital Cardiol (Rome); 2017 Mar; 18(3):188-198. PubMed ID: 28398377
[TBL] [Abstract][Full Text] [Related]
35. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A
J Comp Eff Res; 2019 Feb; 8(3):165-178. PubMed ID: 30654626
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
Aronow WS; Shamliyan TA
Am J Ther; 2019; 26(6):e679-e703. PubMed ID: 30461433
[TBL] [Abstract][Full Text] [Related]
37. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Pan EY; Sobieraj DM
Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
[No Abstract] [Full Text] [Related]
38. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
39. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
40. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
